Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project
Dyslipidaemia plays a major role in the pathogenesis of atherosclerosis. Every year, scientific institutions publish cardiovascular prevention guidelines with updated goals and recommendations based on new evidence. However, medical barriers exist that make achieving these goals difficult and gaps b...
Guardado en:
Autores principales: | Ricardo Lopez Santi, Felipe Martinez, Adrian Baranchuk, Alvaro Sosa Liprandi, Daniel Piskorz, Alberto Lorenzatti, Juan Carlos Kaski |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Radcliffe Medical Media
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4cc6b34f5eb04d13b4ba90713e405361 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
por: Alberto J Lorenzatti, et al.
Publicado: (2020) -
Emerging Strategies for the Management of Atherogenic Dyslipidaemia
por: Anandita Agarwala, et al.
Publicado: (2020) -
Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Mauro Gori, et al.
Publicado: (2021) -
Chagas Disease and Heart Failure: An Expanding Issue Worldwide
por: Felipe Martinez, et al.
Publicado: (2019) -
Sudden Cardiac Death Risk Stratification and Prevention in Chagas Disease: A Non-systematic Review of the Literature
por: Roberto Keegan, et al.
Publicado: (2020)